Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

SPARC Kips Bay will provide modern facilities for 4,500 City University of New York students and create a clear pathway to ...

In order to make medical school more affordable and accessible while addressing the state's shortage of health care ...

WEST LAFAYETTE, Ind. — Amplified Sciences, a clinical-stage life sciences diagnostic company that develops tests for early, more accurate detection of challenging diseases, starting with pancreatic ...

Austin-based Cassava Sciences has reached a settlement agreement in a years-long investor lawsuit that centered on ...

Partnerships with giants like Eli Lilly and Thermo Fisher Scientific put biotech in the spotlight again, though founders still struggle to find investments in their hometown.

As of Friday, December 19, Cassava Sciences, Inc.’s SAVA share price has dipped by 17.37%, which has investors questioning if this is right time to buy.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General ...

The real estate investment trust has been dealing with challenges in the life-sciences market, and its strategy includes ...

RPG Life Sciences Limited ( ($IN:RPGLIFE) ) has issued an update. RPG Life Sciences Limited has incorporated a wholly owned subsidiary named RPG ...

According to Benzinga Pro, SELLAS Life Sciences Group Inc's peer group average for short interest as a percentage of float is ...